Difference between revisions of "Napsin A"
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
*[[Lung adenocarcinoma]] - 83% of cases.<ref name=pmid19740516>{{Cite journal | last1 = Bishop | first1 = JA. | last2 = Sharma | first2 = R. | last3 = Illei | first3 = PB. | title = Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. | journal = Hum Pathol | volume = 41 | issue = 1 | pages = 20-5 | month = Jan | year = 2010 | doi = 10.1016/j.humpath.2009.06.014 | PMID = 19740516 }}</ref> | *[[Lung adenocarcinoma]] - 83% of cases.<ref name=pmid19740516>{{Cite journal | last1 = Bishop | first1 = JA. | last2 = Sharma | first2 = R. | last3 = Illei | first3 = PB. | title = Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. | journal = Hum Pathol | volume = 41 | issue = 1 | pages = 20-5 | month = Jan | year = 2010 | doi = 10.1016/j.humpath.2009.06.014 | PMID = 19740516 }}</ref> | ||
*[[Papillary renal cell carcinoma]] 79% of cases.<ref name=pmid19740516/> | *[[Papillary renal cell carcinoma]] 79% of cases.<ref name=pmid19740516/> | ||
*[[Renal oncocytoma]] 57% of cases.<ref name=pmid25889632>{{Cite journal | last1 = Zhu | first1 = B. | last2 = Rohan | first2 = SM. | last3 = Lin | first3 = X. | title = Immunoexpression of napsin A in renal neoplasms. | journal = Diagn Pathol | volume = 10 | issue = | pages = 4 | month = Mar | year = 2015 | doi = 10.1186/s13000-015-0242-z | PMID = 25889632 }}</ref> | |||
===Occasionally positive=== | ===Occasionally positive=== | ||
*[[Clear cell renal cell carcinoma]] - 34% of cases.<ref name=pmid19740516/> | *[[Clear cell renal cell carcinoma]] - 34% of cases.<ref name=pmid19740516/> | ||
*[[Papillary thyroid carcinoma]] - 2/81 cases, tall cell variant only.<ref name=pmid19740516/> | *[[Papillary thyroid carcinoma]] - 2/81 cases, tall cell variant only.<ref name=pmid19740516/> | ||
*[[Clear cell tubulopapillary RCC]] - 47% of cases.<ref name=pmid25889632/> | |||
==Negative== | ==Negative== | ||
Latest revision as of 14:55, 10 October 2019
Napsin A, also napsin, is a commonly used immunostain in pulmonary pathology.
Positive
- Lung adenocarcinoma - 83% of cases.[1]
- Papillary renal cell carcinoma 79% of cases.[1]
- Renal oncocytoma 57% of cases.[2]
Occasionally positive
- Clear cell renal cell carcinoma - 34% of cases.[1]
- Papillary thyroid carcinoma - 2/81 cases, tall cell variant only.[1]
- Clear cell tubulopapillary RCC - 47% of cases.[2]
Negative
- Squamous cell carcinoma of the lung.[1]
- Colorectal adenocarcinoma.[1]
- Pancreatic adenocarcinoma.[1]
- Breast carcinoma (0 positive of 17 cases[1]).
Napsin in pulomonary adenocarcinoma (WC/Yale Rosen)
Coarse Napsin staining pattern (WC/Yale Rosen)
.jpg)
.jpg)
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Bishop, JA.; Sharma, R.; Illei, PB. (Jan 2010). "Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.". Hum Pathol 41 (1): 20-5. doi:10.1016/j.humpath.2009.06.014. PMID 19740516.
- ↑ 2.0 2.1 Zhu, B.; Rohan, SM.; Lin, X. (Mar 2015). "Immunoexpression of napsin A in renal neoplasms.". Diagn Pathol 10: 4. doi:10.1186/s13000-015-0242-z. PMID 25889632.